Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction
Tóm tắt
Micafungin is an echinocandin with potent activity against a broad range of fungal species, including Candida species. The pharmacokinetic and safety profiles of micafungin have been evaluated in individuals with mild-to-moderate hepatic dysfunction, but not in individuals with severe hepatic dysfunction. Therefore, the present study assessed the pharmacokinetics and safety of a single 100 mg dose of micafungin in healthy subjects (n = 8) and subjects with severe hepatic dysfunction (n = 8). Mean maximum plasma concentration of micafungin and mean area under the plasma micafungin concentration–time curve extrapolated to infinity were lower in subjects with severe hepatic dysfunction (7.3 ± 2.4 µg/mL and 100.1 ± 34.5 h·μg/mL, respectively) than in subjects with normal hepatic function (10.3 ± 2.5 µg/mL and 142.4 ± 28.9 h·μg/mL, respectively). Mean clearance was higher in subjects with severe hepatic dysfunction (1,098 ± 347 mL/h) than in subjects with normal hepatic function (728 ± 149 mL/h). Concentrations of albumin in subjects with severe hepatic dysfunction were lower. Assessments of micafungin plasma protein binding suggested that the higher clearance in subjects with severe hepatic dysfunction may be due to higher unbound concentrations. However, the magnitude of the differences was not considered clinically meaningful and is comparable with exposures reported elsewhere for a 100-mg dose in patients treated for invasive candidiasis. Thus, dose adjustment in subjects with severe hepatic dysfunction is not warranted. Micafungin was well tolerated in all subjects throughout the study.
Tài liệu tham khảo
Astellas Pharma (2013) Mycamine: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000734/WC500031075.pdf. Accessed 19 March 2012
Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ (2010) Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 8∝7(1):93–99. doi:10.1038/clpt.2009.200
de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, Llanos EA, Fisco C, Lau W, Buell D (2005) A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21(7):899–907. doi:10.1111/j.1365-2036.2005.02427.x
Dowell JA, Stogniew M, Krause D, Damle B (2007) Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 47(4):461–470. doi:10.1177/0091270006297227
Fromtling RA (2002) Micafungin sodium (FK-463). Drugs Today (Barc) 38(4):245–257
Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, Bekersky I, Walsh TJ (2001) Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 45(12):3322–3327. doi:10.1128/AAC.45.12.3322-3327.2001
Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I (2005a) Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45(9):1018–1024. doi:10.1177/0091270005279274
Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I (2005b) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45(10):1145–1152. doi:10.1177/0091270005279580
Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, Bekersky I (2005c) Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45(8):954–960. doi:10.1177/0091270005278601
Jarvis B, Figgitt DP, Scott LJ (2004) Micafungin. Drugs 64(9):969–982
Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A (2007) Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 51(2):787–790. doi:10.1128/AAC.00673-06
Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519–1527. doi:10.1016/S0140-6736(07)60605-9
Lass-Flörl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52(3):197–205
Merck Sharp & Dohme Limited (2011) Cancidas (caspofungin) summary of product characteristics. Merck Sharp & Dohme Limited. http://www.medicines.org.uk/emc/medicine/12843#PHARMACOKINETIC_PROPS. Accessed 19 March 2012
Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA (2006) Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 44(2):324–326. doi:10.1128/JCM.44.2.324-326.2006
Mistry GC, Migoya E, Deutsch PJ, Winchell G, Hesney M, Li S, Bi S, Dilzer S, Lasseter KC, Stone JA (2007) Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol 47(8):951–961. doi:10.1177/0091270007303764
Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45(7):883–893. doi:10.1086/520980
Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133–163. doi:10.1128/CMR.00029-06
Pfizer Inc. (2010) Eraxis™ (anidulafungin) prescribing information. Pfizer Inc., http://labeling.pfizer.com/ShowLabeling.aspx?id=566. Accessed 19 March 2012
Undre N, Stevenson P, Baraldi E (2012a) Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis. Eur J Drug Metab Pharmacokinet 37(1):31–38. doi:10.1007/s13318-011-0063-8
Undre N, Stevenson P, Kuse ER, demeyer I (2012b) Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidemia. Open J Med Microbiol 2(3):84–90. doi:10.4236/ojmm.2012.23012
Undre NA, Stevenson P, Freire A, Arrieta A (2012c) Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J 31(6):630–632. doi:10.1097/INF.0b013e31824ab9b0
van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407–1416. doi:10.1086/422312
van der Elst KC, Brüggemann RJ, Rodgers MG, Alffenaar JW (2012) Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transpl Infect Dis 14(4):440–443. doi:10.1111/j.1399-3062.2011.00716.x
Wiederhold NP, Lewis JS 2nd (2007) The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 8(8):1155–1166. doi:10.1517/14656566.8.8.1155
Yamato Y, Kaneko H, Tanimoto K, Katashima M, Ishibashi K, Kawamura A, Terakawa M, Kagayama A (2002) Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn J Chemother 50:68–73